{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:35:46Z","timestamp":1789785346666,"version":"4.0.1"},"reference-count":99,"publisher":"Impact Journals, LLC","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,6,7]]},"DOI":"10.18632\/oncotarget.8154","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T01:53:21Z","timestamp":1458266001000},"page":"35466-35477","source":"Crossref","is-referenced-by-count":52,"title":["Multiple myeloma cancer stem cells"],"prefix":"10.18632","volume":"7","author":[{"given":"Minjie","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumei","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,3,17]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Bergsagel","year":"2012","journal-title":"The Journal of clinical investigation"},{"key":"2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Zweegman","year":"2014","journal-title":"The Lancet Oncology"},{"key":"3","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"Bornhauser","year":"2015","journal-title":"Lancet"},{"key":"4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Anderson","year":"2007","journal-title":"Nature reviews Cancer"},{"key":"5","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Anderson","year":"2011","journal-title":"The New England journal of medicine"},{"key":"6","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S1470-2045(14)70372-9","article-title":"An oral proteasome inhibitor for multiple myeloma","volume":"15","author":"Pratt","year":"2014","journal-title":"The Lancet Oncology"},{"key":"7","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S1470-2045(14)70443-7","article-title":"Panobinostat for the treatment of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"The Lancet Oncology"},{"key":"8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Weissman","year":"2001","journal-title":"Nature"},{"key":"9","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature05372","article-title":"A human colon cancer cell capable of initiating tumour growth in immunodeficient mice","volume":"445","author":"Dick","year":"2007","journal-title":"Nature"},{"key":"10","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Dick","year":"1997","journal-title":"Nature medicine"},{"key":"11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/stem.1031","article-title":"Colorectal cancer stem cells","volume":"30","author":"Papavassiliou","year":"2012","journal-title":"Stem cells"},{"key":"12","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/stem.30","article-title":"Identification of gastric cancer stem cells using the cell surface marker CD44","volume":"27","author":"Wang","year":"2009","journal-title":"Stem cells"},{"key":"13","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1172\/JCI66024","article-title":"Cancer stem cells in the development of liver cancer","volume":"123","author":"Wang","year":"2013","journal-title":"The Journal of clinical investigation"},{"key":"14","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/0008-5472.CAN-06-2030","article-title":"Identification of pancreatic cancer stem cells","volume":"67","author":"Simeone","year":"2007","journal-title":"Cancer research"},{"key":"15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Weissman","year":"2009","journal-title":"Cell"},{"key":"16","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Jones","year":"2004","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1038\/leu.2012.140","article-title":"CD19-CD45 low\/- CD38 high\/CD138+ plasma cells enrich for human tumorigenic myeloma cells","volume":"26","author":"Weissman","year":"2012","journal-title":"Leukemia"},{"key":"18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood-2012-06-436220","article-title":"Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma","volume":"121","author":"Reid","year":"2013","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.stem.2011.01.007","article-title":"Critical appraisal of the side population assay in stem cell and cancer stem cell research","volume":"8","author":"Niclou","year":"2011","journal-title":"Cell stem cell"},{"key":"20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.03.048","article-title":"Side population cells in human cancers","volume":"268","author":"Alman","year":"2008","journal-title":"Cancer letters"},{"key":"21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance","volume":"68","author":"Jones","year":"2008","journal-title":"Cancer research"},{"key":"22","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1158\/1078-0432.CCR-12-0531","article-title":"Stemness of B-cell progenitors in multiple myeloma bone marrow","volume":"18","author":"Perez","year":"2012","journal-title":"Clinical cancer research"},{"key":"23","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood-2008-02-142430","article-title":"A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma","volume":"112","author":"Pilarski","year":"2008","journal-title":"Blood"},{"key":"24","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1182\/blood.V94.10.3576.422k01_3576_3582","article-title":"The proliferative potential of myeloma plasma cells manifest in the SCID-hu host","volume":"94","author":"Epstein","year":"1999","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/sj.leu.2403513","article-title":"The SCID-rab model: a novelsystem for primary human myeloma demonstrating growth of CD138-expressing malignant cells","volume":"18","author":"Yaccoby","year":"2004","journal-title":"Leukemia"},{"key":"26","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/leu.2012.80","article-title":"CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients","volume":"26","author":"Kimura","year":"2012","journal-title":"Leukemia"},{"key":"27","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3324\/haematol.2011.057372","article-title":"CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype","volume":"97","author":"San Miguel","year":"2012","journal-title":"Haematologica"},{"key":"28","doi-asserted-by":"crossref","first-page":"e31998","DOI":"10.1371\/journal.pone.0031998","article-title":"Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myeloma","volume":"7","author":"Binder","year":"2012","journal-title":"PloS one"},{"key":"29","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1365-2141.2011.08904.x","article-title":"The peripheral CD138+ population but not the CD138- population contains myeloma clonogenic cells in plasma cell leukaemia patients","volume":"156","author":"Pellat-Deceunynck","year":"2012","journal-title":"British journal of haematology"},{"key":"30","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1182\/blood-2010-02-267344","article-title":"Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications","volume":"117","author":"Anderson","year":"2011","journal-title":"Blood"},{"key":"31","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/bjh.12563","article-title":"Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma","volume":"163","author":"Svachova","year":"2013","journal-title":"British journal of haematology"},{"key":"32","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/stem.1643","article-title":"Concise review: Defining and targeting myeloma stem cell-like cells","volume":"32","author":"Matsumoto","year":"2014","journal-title":"Stem cells"},{"key":"33","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1084\/jem.183.4.1797","article-title":"Isolation and functional properties of murine hematopoietic stem cells that are replicating","volume":"183","author":"Mulligan","year":"1996","journal-title":"The Journal of experimental medicine"},{"key":"34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/stemcells.2005-0116","article-title":"A side order of stem cells: the SP phenotype","volume":"24","author":"Little","year":"2006","journal-title":"Stem cells"},{"key":"35","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1080\/10428190802272676","article-title":"Presence of Hoechst low side populations in multiple myeloma","volume":"49","author":"Sze","year":"2008","journal-title":"Leukemia & lymphoma"},{"key":"36","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.yexcr.2004.04.010","article-title":"Demystifying SP cell purification: viability, yield, and phenotype are defined by isolation parameters","volume":"298","author":"Kunkel","year":"2004","journal-title":"Experimental cell research"},{"key":"37","first-page":"1977","article-title":"Thalidomide in elderly patients with multiple myeloma","volume":"367","author":"Kami","year":"2006","journal-title":"Lancet"},{"key":"38","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0140-6736(05)75677-4","article-title":"Low-dose thalidomide seems to be effective in multiple myeloma","volume":"354","author":"Larkin","year":"1999","journal-title":"Lancet"},{"key":"39","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study","volume":"376","author":"Deliliers","year":"2010","journal-title":"Lancet"},{"key":"40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"San-Miguel","year":"2015","journal-title":"The New England journal of medicine"},{"key":"41","doi-asserted-by":"publisher","first-page":"40496","DOI":"10.18632\/oncotarget.5800","article-title":"Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?","volume":"6","author":"Tricot","year":"2015","journal-title":"Oncotarget"},{"key":"42","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.V83.3.724.724","article-title":"Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma","volume":"83","author":"Belch","year":"1994","journal-title":"Blood"},{"key":"43","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/sj.bmt.1701767","article-title":"Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation","volume":"23","author":"Moos","year":"1999","journal-title":"Bone marrow transplantation"},{"key":"44","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1365-2141.1999.01548.x","article-title":"Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation","volume":"106","author":"Moos","year":"1999","journal-title":"British journal of haematology"},{"key":"45","first-page":"1","article-title":"The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade","volume":"18C","author":"Chen","year":"2015","journal-title":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"key":"46","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood.V122.21.5404.5404","article-title":"RARalpha2 expression confers myeloma stem cell features","volume":"122","author":"Tricot","year":"2013","journal-title":"Blood"},{"key":"47","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/0008-5472.CAN-14-2362","article-title":"Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma","volume":"75","author":"Zhan","year":"2015","journal-title":"Cancer research"},{"key":"48","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ajh.23387","article-title":"Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1","volume":"88","author":"Hawley","year":"2013","journal-title":"American journal of hematology"},{"key":"49","doi-asserted-by":"crossref","first-page":"14228","DOI":"10.1073\/pnas.0400067101","article-title":"A distinct \u201cside population\u201d of cells with high drug efflux capacity in human tumor cells","volume":"101","author":"Brenner","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"50","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.4161\/cc.10.9.15486","article-title":"Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform","volume":"10","author":"Lee","year":"2011","journal-title":"Cell cycle"},{"key":"51","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(05)66515-4","article-title":"Aplastic anaemia","volume":"365","author":"Jones","year":"2005","journal-title":"Lancet"},{"key":"52","doi-asserted-by":"crossref","first-page":"e10277","DOI":"10.1371\/journal.pone.0010277","article-title":"Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers","volume":"5","author":"Zhang","year":"2010","journal-title":"PloS one"},{"key":"53","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/0008-5472.CAN-14-1924","article-title":"Aldehyde Dehydrogenase Is Regulated by beta-Catenin\/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells","volume":"75","author":"Dubrovska","year":"2015","journal-title":"Cancer research"},{"key":"54","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","article-title":"ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome","volume":"1","author":"Dontu","year":"2007","journal-title":"Cell stem cell"},{"key":"55","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/leu.2013.383","article-title":"ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma","volume":"28","author":"Zhan","year":"2014","journal-title":"Leukemia"},{"key":"56","doi-asserted-by":"publisher","first-page":"11986","DOI":"10.18632\/oncotarget.2388","article-title":"NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma","volume":"5","author":"Zhan","year":"2014","journal-title":"Oncotarget"},{"key":"57","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1158\/1078-0432.CCR-08-1479","article-title":"Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers","volume":"15","author":"Noguchi","year":"2009","journal-title":"Clinical cancer research"},{"key":"58","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.biopha.2013.04.005","article-title":"The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance","volume":"67","author":"Zabel","year":"2013","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"key":"59","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1158\/0008-5472.CAN-13-3456","article-title":"The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation","volume":"74","author":"Settleman","year":"2014","journal-title":"Cancer research"},{"key":"60","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1126\/science.287.5459.1804","article-title":"Hematopoietic stem cell quiescence maintained by p21cip1\/waf1","volume":"287","author":"Scadden","year":"2000","journal-title":"Science"},{"key":"61","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.yexcr.2010.03.013","article-title":"Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells","volume":"316","author":"Bos","year":"2010","journal-title":"Experimental cell research"},{"key":"62","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.stem.2008.01.003","article-title":"Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal","volume":"2","author":"Scadden","year":"2008","journal-title":"Cell stem cell"},{"key":"63","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrclinonc.2015.61","article-title":"Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update","volume":"12","author":"Ivy","year":"2015","journal-title":"Nature reviews Clinical oncology"},{"key":"64","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1172\/JCI76611","article-title":"NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells","volume":"124","author":"Lei","year":"2014","journal-title":"The Journal of clinical investigation"},{"key":"65","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1038\/ncomms5806","article-title":"Sphingosine-1-phosphate promotes expansion of cancer stem cellsS1PR3 by a ligand-independent Notch activation","volume":"5","author":"Kanda","year":"2014","journal-title":"Nature communications"},{"key":"66","doi-asserted-by":"publisher","first-page":"32039","DOI":"10.18632\/oncotarget.5055","article-title":"PI3K\/AKT\/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth","volume":"6","author":"Srivastava","year":"2015","journal-title":"Oncotarget"},{"key":"67","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1517\/14728222.2011.577418","article-title":"Targeting the Wnt\/beta-catenin signaling pathway in human cancers","volume":"15","author":"Maekawa","year":"2011","journal-title":"Expert opinion on therapeutic targets"},{"key":"68","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nature03319","article-title":"Wnt signalling in stem cells and cancer","volume":"434","author":"Clevers","year":"2005","journal-title":"Nature"},{"key":"69","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ydbio.2005.11.011","article-title":"WNT\/beta-catenin pathway up-regulates Stat3 and converges on LIF to prevent differentiation of mouse embryonic stem cells","volume":"290","author":"Zhao","year":"2006","journal-title":"Developmental biology"},{"key":"70","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1073\/pnas.0305855101","article-title":"Illegitimate WNT signaling promotes proliferation of multiple myeloma cells","volume":"101","author":"Pals","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"71","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1073\/pnas.0610299104","article-title":"Targeting the beta-catenin\/TCF transcriptional complex in the treatment of multiple myeloma","volume":"104","author":"Carrasco","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"72","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1158\/0008-5472.CAN-13-3311-T","article-title":"miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt\/beta-catenin\/BCL9 pathway","volume":"74","author":"Hideshima","year":"2014","journal-title":"Cancer research"},{"key":"73","first-page":"1425","article-title":"Targeting hedgehog signaling in cancer: research and clinical developments","volume":"6","author":"Gu","year":"2013","journal-title":"OncoTargets and therapy"},{"key":"74","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2174\/187152010790909344","article-title":"Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis","volume":"10","author":"Matsui","year":"2010","journal-title":"Anti-cancer agents in medicinal chemistry"},{"key":"75","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1158\/1078-0432.CCR-11-2509","article-title":"Molecular pathways: the hedgehog signaling pathway in cancer","volume":"18","author":"Matsui","year":"2012","journal-title":"Clinical cancer research"},{"key":"76","doi-asserted-by":"crossref","first-page":"14134","DOI":"10.1073\/pnas.0604568103","article-title":"Hedgehog modulates cell cycle regulators in stem cells to control hematopoietic regeneration","volume":"103","author":"Bhatia","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"77","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1073\/pnas.0611682104","article-title":"Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma","volume":"104","author":"Matsui","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"78","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1182\/blood-2014-03-557298","article-title":"A critical role of autocrine sonic hedgehog signaling in human CD138+ myeloma cell survival and drug resistance","volume":"124","author":"Yi","year":"2014","journal-title":"Blood"},{"key":"79","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/blood-2003-07-2340","article-title":"Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines","volume":"103","author":"Gabrilovich","year":"2004","journal-title":"Blood"},{"key":"80","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1182\/blood-2003-07-2254","article-title":"Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells","volume":"103","author":"Dorken","year":"2004","journal-title":"Blood"},{"key":"81","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/leu.2008.138","article-title":"Notch inhibition blocks multiple myeloma cell-induced osteoclast activation","volume":"22","author":"Jundt","year":"2008","journal-title":"Leukemia"},{"key":"82","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survivalcell-cell contact: a vicious cycle between bone destruction and myeloma expansion","volume":"104","author":"Matsumoto","year":"2004","journal-title":"Blood"},{"key":"83","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2007-07-102632","article-title":"Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy","volume":"111","author":"Gabrilovich","year":"2008","journal-title":"Blood"},{"key":"84","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/leu.2013.27","article-title":"Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrowthe chemokine system CXCR4\/SDF-1","volume":"27","author":"Chiaramonte","year":"2013","journal-title":"Leukemia"},{"key":"85","doi-asserted-by":"publisher","first-page":"10393","DOI":"10.18632\/oncotarget.2084","article-title":"Notch signaling drives multiple myeloma induced osteoclastogenesis","volume":"5","author":"Chiaramonte","year":"2014","journal-title":"Oncotarget"},{"key":"86","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4252\/wjsc.v7.i1.84","article-title":"Identify multiple myeloma stem cells: Utopia?","volume":"7","author":"Ria","year":"2015","journal-title":"World journal of stem cells"},{"key":"87","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1038\/sj.onc.1205664","article-title":"Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteinsthe IGF-1\/Akt signaling in human multiple myeloma cells: therapeutic implications","volume":"21","author":"Anderson","year":"2002","journal-title":"Oncogene"},{"key":"88","article-title":"Therapeutic potential of mTOR inhibitors for targeting cancer stem cells","author":"Lagasse","year":"2015","journal-title":"British journal of clinical pharmacology"},{"key":"89","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/0008-5472.CAN-14-1223","article-title":"PI3K\/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells","volume":"75","author":"Xu","year":"2015","journal-title":"Cancer research"},{"key":"90","doi-asserted-by":"publisher","first-page":"14993","DOI":"10.18632\/oncotarget.3802","article-title":"MicroRNA-451 regulates stemness of side population cellsPI3K\/Akt\/mTOR signaling pathway in multiple myeloma","volume":"6","author":"Hou","year":"2015","journal-title":"Oncotarget"},{"key":"91","doi-asserted-by":"crossref","first-page":"8395","DOI":"10.1007\/s13277-014-2264-7","article-title":"MicroRNAs in cancer stem cells: current status and future directions","volume":"35","author":"Saini","year":"2014","journal-title":"Tumour biology"},{"key":"92","doi-asserted-by":"publisher","first-page":"40496","DOI":"10.18632\/oncotarget.5800","article-title":"Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?","volume":"6","author":"Tricot","year":"2015","journal-title":"Oncotarget"},{"key":"93","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood.V98.2.428","article-title":"Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration","volume":"98","author":"Anderson","year":"2001","journal-title":"Blood"},{"key":"94","first-page":"1","article-title":"Niche for normal and cancer stem cells","author":"Osawa","year":"2006","journal-title":"Ernst Schering Foundation symposium proceedings"},{"key":"95","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1756-8722-6-91","article-title":"Fact or fiction\u2014identifying the elusive multiple myeloma stem cell","volume":"6","author":"Li","year":"2013","journal-title":"Journal of hematology & oncology"},{"key":"96","first-page":"810","article-title":"Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression","volume":"90","author":"Vanderkerken","year":"2005","journal-title":"Haematologica"},{"key":"97","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"Friend","year":"2002","journal-title":"Nature"},{"key":"98","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1056\/NEJMoa040465","article-title":"Prognostically useful gene-expression profiles in acute myeloid leukemia","volume":"350","author":"Delwel","year":"2004","journal-title":"The New England journal of medicine"},{"key":"99","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2005.05.026","article-title":"SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells","volume":"121","author":"Morrison","year":"2005","journal-title":"Cell"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.8154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T08:49:39Z","timestamp":1600332579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.8154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,17]]},"references-count":99,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2016,6,7]]}},"alternative-id":["8154","27007154"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.8154","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,17]]}}}